Royalty PharmaMEX:RPRXN 72 Current Ratio is 2.66 as of Mar. 2026, which is 41% below its 10-year median of 4.50. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review. Among 1,417 Biotechnology companies, Royalty Pharma ranks worse than 60.76% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Royalty Pharma's current ratio for the quarter that ended in Mar. 2026 was 2.66.
Royalty Pharma has a current ratio of 2.66. It generally indicates good short-term financial strength.
The historical rank and industry rank for Royalty Pharma's Current Ratio or its related term are showing as below:
MEX:RPRXN'
s Current Ratio Range Over the Past 10 Years
Min: 1.26 Med: 4.5 Max: 21.95
Current: 2.66
During the past 9 years, Royalty Pharma's highest Current Ratio was 21.95. The lowest was 1.26. And the median was 4.50.
MEX:RPRXN's Current Ratio is ranked worse than 60.76% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs MEX:RPRXN: 2.66
Royalty Pharma (MEX:RPRXN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Royalty Pharma Current Ratio Related Terms
Royalty Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RPRXN vs BNTX, INSM, ROIV: Current Ratio Comparison
For the Biotechnology subindustry, Royalty Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (MEX:RPRXN) has a Current Ratio of 2.66 as of Mar. 2026. This is 41% below median its historical median of 4.50. Over the past decade, Royalty Pharma's Current Ratio has ranged from 1.26 to 21.95. According to the industry distribution chart, Royalty Pharma ranks #861 out of 1417 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Royalty Pharma's Current Ratio too high?
Royalty Pharma's current Current Ratio of 2.66 is 41% below median its 10-year median of 4.50. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 21.95. The Biotechnology industry median Current Ratio is 3.89. Royalty Pharma's value of 2.66 is 31.6% below this industry median. Based on the distribution chart, Royalty Pharma ranks #861 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Current Ratio compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #861 out of 1417 companies for Current Ratio. This places Royalty Pharma in the lower half of its industry. The industry median Current Ratio is 3.89. Royalty Pharma's value of 2.66 is 31.6% below this benchmark. Historically, Royalty Pharma's own Current Ratio has ranged from 1.26 to 21.95 over the past decade. While the company's 10-year median is 4.50 vs. the industry median of 3.89, Royalty Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Royalty Pharma's current Current Ratio of 2.66 is 31.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Current Ratio is 2.66, which is 41% below median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Current Ratio of 2.66. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Current Ratio is 2.66, which is 41% below median its 10-year median of 4.50 and 31.6% below the Biotechnology industry median of 3.89. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Current Ratio is 2.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.
Key valuation signals for MEX:RPRXN:
Current Ratio: 2.66 (41% below median its 10-year median of 4.50)
GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
Industry Position: 31.6% below the Biotechnology median (#861 of 1417)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for MEX:RPRXN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
